Xeris Biopharma Reports Q3 EPS of $0.06
Q3 EPS was $0.06, versus the FactSet estimate of $0.02.
Related stories
LCI Industries Q3 Sales Fall 4%, Miss Estimates
M impact | EARNINGS | Nov 05, 2026, 12:54 PM UTC
LCI Industries expects 2026 adjusted EPS of $8.25-$8.50
LCI Industries expects 2026 adjusted EPS of $8.25 to $8.50, versus a FactSet estimate of $8.40.
M impact | EARNINGS | Nov 05, 2026, 12:53 PM UTC
Enviri Reports $47 Million Adjusted EBITDA and $0.16 GAAP EPS
Enviri reported third-quarter 2026 revenue of $325 million and income from continuing operations of $6 million. Adjusted EBITDA rose 21% year over year to $47 million; adjusted dil
M impact | EARNINGS | Nov 05, 2026, 12:53 PM UTC
Cars.com Reports $181.9 Million Revenue and 113% Net Income Growth
Cars.com reported third-quarter 2026 revenue of $181.9 million, up slightly year over year, and net income of $16.3 million, up 113%. Adjusted EBITDA was $55.8 million, and adjuste
M impact | EARNINGS | Nov 05, 2026, 12:53 PM UTC
LCI Industries Expects 2026 Revenue of $3.9B to $4.0B
LCI Industries expects 2026 revenue of $3.9 billion to $4.0 billion, versus a FactSet estimate of $3.99 billion.
M impact | EARNINGS | Nov 05, 2026, 12:53 PM UTC
McGraw Hill Expects Fiscal 2027 Revenue of $2.12B-$2.18B
McGraw Hill expects fiscal 2027 revenue of $2.12 billion to $2.18 billion, versus a FactSet estimate of $2.15 billion.
M impact | EARNINGS | Nov 05, 2026, 12:52 PM UTC